$0.81
-0.02 (-1.85%)
Open$0.84
Previous Close$0.83
Day High$0.84
Day Low$0.80
52W High$2.25
52W Low$0.49
Volume—
Avg Volume170.9K
Market Cap76.88M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,835.9% upside
Current
$0.81
$0.81
Target
$31.94
$31.94
$22.24
$31.94 avg
$42.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.40M | 13.64M | 13.89M |
| Net Income | -704,326 | -740,627 | -795,931 |
| Profit Margin | -4.6% | -5.4% | -5.7% |
| EBITDA | -1,183,474 | -997,072 | -1,062,628 |
| Free Cash Flow | -738,508 | -859,127 | -679,392 |
| Rev Growth | +4.1% | +16.3% | -0.4% |
| Debt/Equity | 0.22 | 0.30 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |